Price · as of 2024-12-31
$1.45
Market cap 194.57M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $19.89 | +1,271.72% |
| Intrinsic Value(DCF) | $0.88 | -39.31% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | $0.00 | $1.31 | |||
| 2017 | $967.50 | $415.29 | $0.06 | $0.00 | $0.00 |
| 2018 | $840.00 | $365.57 | $0.09 | $0.00 | $1.96 |
| 2019 | $219.00 | $527.64 | $7.01 | $0.00 | $0.00 |
| 2020 | $402.50 | $208.61 | $2,796.23 | $0.00 | $0.00 |
| 2021 | $60.50 | $51.32 | $79.69 | $0.00 | $0.00 |
| 2022 | $17.75 | $41.07 | $0.00 | $0.00 | $2.54 |
| 2023 | $19.75 | $49.00 | $0.00 | $0.00 | $0.00 |
| 2024 | $2.21 | $19.89 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Cibus, Inc.'s (CBUS) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $19.89
- Current price
- $1.45
- AI upside
- +1,271.72%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$0.88
-39.31% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| CBUS | Cibus, Inc. | $1.45 | 194.57M | +1,272% | -39% | — | — | -0.18 | 0.56 | 12.04 | -0.30 | — | -0.26 | 100.00% | -6062.79% | -5898.36% | -146.63% | -129.39% | -63.21% | 0.39 | -7.56 | 0.85 | 0.78 | -0.09 | -5827.00% | 13456.00% | 1647.00% | -114.67% | -2.92 | -29.47% | 0.00% | 0.00% | 0.00% | -0.28 | -1.24 | 17.17 | -5.24 |
| ACRV | Acrivon Therapeutics, Inc… | $1.51 | 47.65M | — | — | — | — | -2.63 | 1.20 | — | -0.46 | — | 1.20 | 0.00% | — | — | -54.07% | 26706.29% | -48.11% | 0.02 | — | 10.55 | 10.43 | 0.45 | -2336.00% | — | 5579.00% | -32.26% | -3.81 | 20490.12% | 0.00% | 0.00% | 2.26% | -0.41 | -0.53 | — | 4.53 |
| BMEA | Biomea Fusion, Inc. | $1.37 | 81.51M | — | — | — | — | -0.71 | 1.90 | — | -0.34 | -6.23 | 1.90 | 0.00% | — | — | -125.38% | -6089.18% | -98.92% | 0.17 | — | 3.15 | 2.69 | 0.35 | 1134.00% | — | 2030.00% | -122.90% | -5.53 | -5082.67% | 0.00% | 0.00% | 0.00% | -0.34 | -0.40 | — | -9.96 |
| CAMP | CAMP4 Therapeutics Corpor… | $4.49 | 95.37M | — | -59% | — | — | -1.58 | 1.29 | 125.35 | -0.51 | -0.81 | 1.29 | 100.00% | -8142.33% | -7943.40% | 719.97% | 75.53% | -57.27% | 0.14 | — | 6.92 | 6.68 | 1.08 | 19556.00% | — | 807.00% | -56.29% | -4.75 | 65.45% | 0.00% | 0.00% | 0.00% | -0.50 | -0.57 | 40.39 | -1.91 |
| IMUX | Immunic, Inc. | $1.02 | 100.66M | — | — | — | — | -16.98 | -247.31 | — | -16.85 | — | -247.31 | 0.00% | — | — | -1653.15% | 539.27% | -299.36% | -0.02 | — | 0.75 | 0.64 | 0.16 | -3800.00% | — | 110.00% | -5.21% | -2.80 | 449.10% | 0.00% | 0.00% | 0.00% | -15.84 | -19.02 | — | -17.75 |
| MNOV | MediciNova, Inc. | $1.45 | 71.26M | — | -41% | — | — | -5.77 | 1.66 | 168.87 | -3.22 | -132.62 | 2.16 | 7.58% | -3242.47% | -2928.78% | -25.50% | -113.96% | -23.65% | 0.00 | — | 8.16 | 8.11 | 2.56 | 435.00% | — | -783.00% | -14.18% | -2.58 | -84.16% | 0.00% | 0.00% | 0.00% | -2.90 | -3.93 | 94.15 | -3.37 |
| PMVP | PMV Pharmaceuticals, Inc. | $1.70 | 90.46M | — | — | — | — | -1.08 | 0.36 | — | 1.42 | — | 0.36 | 0.00% | — | — | -29.23% | -306.66% | -26.48% | 0.01 | — | 12.22 | 11.79 | 0.54 | -2096.00% | — | -827.00% | -81.87% | -3.57 | -237.51% | 0.00% | 0.00% | 24.06% | 1.23 | 2.02 | — | -0.66 |
| RLMD | Relmada Therapeutics, Inc… | $4.56 | 334.4M | — | — | — | — | -0.11 | 0.24 | — | 0.43 | — | 0.24 | 0.00% | — | — | -132.33% | 824.32% | -111.57% | 0.00 | — | 4.45 | 4.36 | 0.05 | -1921.00% | — | 19.00% | -597.84% | -5.03 | 508.56% | 0.00% | 0.00% | 0.00% | 0.43 | 0.70 | — | -24.19 |
| RPTX | Repare Therapeutics Inc. | $2.65 | 114.24M | +786% | -68% | — | — | -0.59 | 0.33 | 0.94 | 1.12 | — | 0.33 | 74.98% | -174.88% | -158.37% | -46.63% | 2379.11% | -39.35% | 0.01 | — | 6.77 | 6.53 | 0.92 | -1031.00% | 458.00% | -4078.00% | -152.11% | -3.02 | 1944.67% | 0.00% | 0.00% | 0.00% | 1.08 | 1.32 | -1.88 | -2.58 |
| UNCY | Unicycive Therapeutics, I… | $6.93 | 148.94M | +172% | — | — | — | -1.03 | 5.08 | — | -0.34 | -0.30 | 5.08 | 0.00% | — | — | -2028.11% | 209.66% | -160.18% | 0.10 | -452.35 | 1.28 | 1.08 | 0.70 | 33750.00% | -10000.00% | 5658.00% | -75.83% | -1.18 | 187.01% | 2.90% | -3.00% | 46.52% | -0.39 | -0.43 | — | -6.63 |
About Cibus, Inc.
Cibus, Inc., a agricultural technology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases. The company is based in San Diego, California.
- CEO
- Peter R. Beetham
- Employees
- 157
- Beta
- 1.80
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($0.88 ÷ $1.45) − 1 = -39.31% (DCF, example).